FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740061860> ?p ?o ?g. }

• W2740061860 abstract "The EZH2 inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase 2 clinical trials for the treatment of non-Hodgkin’s Lymphoma (NHL). EZH2 inhibitors have shown anti-proliferative effects in multiple preclinical models of NHL and objective clinical responses have been reported in patients with B-cell lymphomas in phase 1 and phase 2 studies of tazemetostat. Mounting evidence suggests that EZH2 is an important regulator of B cell differentiation, both in normal B-cells and in B-cell lymphoma, and may be an important mediator of cell fate in B-cell malignancies in the clinic. Consistent with its essential role in regulating B cell differentiation, recent studies have also shown a dependence on EZH2 activity in multiple myeloma (MM), a disease arising from terminally-differentiated B-cell lymphocyte plasmablasts. Frequent genetic alterations of epigenetic modulators are observed in MM, pointing towards an important role in the initiation and maintenance of this disease. Dysregulation of the H3K27 methyltransferase EZH2, its corresponding histone demethylase UTX and the H3K36 methyltransferase WHSC1 in MM suggest that disruption of the balance of histone methylation may be fundamental to MM pathogenesis in a subset of cases. Indeed, inhibition of EZH2 alone has shown potent anti-proliferative effects both in in vitro and in vivo preclinical models of MM. Here, we describe the effects of small molecule EZH2 inhibitors as monotherapy and in combination with standard of care agents in preclinical models of MM. Tazemetostat selectively inhibits intracellular H3K27 methylation in MM cell lines and elicits a robust anti-proliferative effect in 14-day assays. Following demonstration of single agent activity, we then investigated potential for combinatorial activity of tazemetostat with first and second line therapies for multiple myeloma as well as other non-approved but emerging therapies. Synergistic anti-proliferative activity was observed when tazemetostat was combined with glucocorticoid receptor agonists (dexamethasone, prednisolone), small molecule immune system modulators (lenalidomide, pomalidomide) and proteasome inhibitors (bortezomib, ixazomib) when cells were primed with tazemetostat for seven days prior to the addition of the standard of care drugs. Combination activity was also observed with an alternate treatment schedule where cells were co-treated with tazemetostat along with the combination partner for seven days. Studies with selected therapeutic modalities were expanded into in vivo xenograft models to further evaluate monotherapy and combination activity of EZH2 inhibitors in MM. Citation Format: Allison E. Drew, Vinny Motwani, John E. Campbell, Cuyue Tang, Jesse J. Smith, Richard Chesworth, Robert A. Copeland, Alejandra Raimondi, Scott Ribich. Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5060. doi:10.1158/1538-7445.AM2017-5060" @default.
• W2740061860 created "2017-08-08" @default.
• W2740061860 creator A5015187022 @default.
• W2740061860 creator A5021168913 @default.
• W2740061860 creator A5027598294 @default.
• W2740061860 creator A5055002979 @default.
• W2740061860 creator A5060751046 @default.
• W2740061860 creator A5067466789 @default.
• W2740061860 creator A5079181273 @default.
• W2740061860 creator A5083683480 @default.
• W2740061860 creator A5088871392 @default.
• W2740061860 date "2017-07-01" @default.
• W2740061860 modified "2023-09-26" @default.
• W2740061860 title "Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models" @default.
• W2740061860 doi "https://doi.org/10.1158/1538-7445.am2017-5060" @default.
• W2740061860 hasPublicationYear "2017" @default.
• W2740061860 type Work @default.
• W2740061860 sameAs 2740061860 @default.
• W2740061860 citedByCount "3" @default.
• W2740061860 countsByYear W27400618602018 @default.
• W2740061860 countsByYear W27400618602019 @default.
• W2740061860 countsByYear W27400618602021 @default.
• W2740061860 crossrefType "proceedings-article" @default.
• W2740061860 hasAuthorship W2740061860A5015187022 @default.
• W2740061860 hasAuthorship W2740061860A5021168913 @default.
• W2740061860 hasAuthorship W2740061860A5027598294 @default.
• W2740061860 hasAuthorship W2740061860A5055002979 @default.
• W2740061860 hasAuthorship W2740061860A5060751046 @default.
• W2740061860 hasAuthorship W2740061860A5067466789 @default.
• W2740061860 hasAuthorship W2740061860A5079181273 @default.
• W2740061860 hasAuthorship W2740061860A5083683480 @default.
• W2740061860 hasAuthorship W2740061860A5088871392 @default.
• W2740061860 hasConcept C104317684 @default.
• W2740061860 hasConcept C203014093 @default.
• W2740061860 hasConcept C2776063141 @default.
• W2740061860 hasConcept C2776364478 @default.
• W2740061860 hasConcept C2779338263 @default.
• W2740061860 hasConcept C2780108899 @default.
• W2740061860 hasConcept C2781098529 @default.
• W2740061860 hasConcept C33288867 @default.
• W2740061860 hasConcept C41091548 @default.
• W2740061860 hasConcept C50171091 @default.
• W2740061860 hasConcept C502942594 @default.
• W2740061860 hasConcept C55493867 @default.
• W2740061860 hasConcept C71924100 @default.
• W2740061860 hasConcept C86803240 @default.
• W2740061860 hasConcept C91965660 @default.
• W2740061860 hasConcept C98274493 @default.
• W2740061860 hasConceptScore W2740061860C104317684 @default.
• W2740061860 hasConceptScore W2740061860C203014093 @default.
• W2740061860 hasConceptScore W2740061860C2776063141 @default.
• W2740061860 hasConceptScore W2740061860C2776364478 @default.
• W2740061860 hasConceptScore W2740061860C2779338263 @default.
• W2740061860 hasConceptScore W2740061860C2780108899 @default.
• W2740061860 hasConceptScore W2740061860C2781098529 @default.
• W2740061860 hasConceptScore W2740061860C33288867 @default.
• W2740061860 hasConceptScore W2740061860C41091548 @default.
• W2740061860 hasConceptScore W2740061860C50171091 @default.
• W2740061860 hasConceptScore W2740061860C502942594 @default.
• W2740061860 hasConceptScore W2740061860C55493867 @default.
• W2740061860 hasConceptScore W2740061860C71924100 @default.
• W2740061860 hasConceptScore W2740061860C86803240 @default.
• W2740061860 hasConceptScore W2740061860C91965660 @default.
• W2740061860 hasConceptScore W2740061860C98274493 @default.
• W2740061860 hasLocation W27400618601 @default.
• W2740061860 hasOpenAccess W2740061860 @default.
• W2740061860 hasPrimaryLocation W27400618601 @default.
• W2740061860 hasRelatedWork W2017768291 @default.
• W2740061860 hasRelatedWork W2032923547 @default.
• W2740061860 hasRelatedWork W2073679029 @default.
• W2740061860 hasRelatedWork W2079877616 @default.
• W2740061860 hasRelatedWork W2326187864 @default.
• W2740061860 hasRelatedWork W2504573995 @default.
• W2740061860 hasRelatedWork W2557763600 @default.
• W2740061860 hasRelatedWork W2593366496 @default.
• W2740061860 hasRelatedWork W2613680501 @default.
• W2740061860 hasRelatedWork W2740072246 @default.
• W2740061860 hasRelatedWork W2741659768 @default.
• W2740061860 hasRelatedWork W2747620054 @default.
• W2740061860 hasRelatedWork W2885079084 @default.
• W2740061860 hasRelatedWork W2885575942 @default.
• W2740061860 hasRelatedWork W2896240697 @default.
• W2740061860 hasRelatedWork W2944523504 @default.
• W2740061860 hasRelatedWork W2993877655 @default.
• W2740061860 hasRelatedWork W3009522834 @default.
• W2740061860 hasRelatedWork W3112350425 @default.
• W2740061860 hasRelatedWork W3119162564 @default.
• W2740061860 isParatext "false" @default.
• W2740061860 isRetracted "false" @default.
• W2740061860 magId "2740061860" @default.
• W2740061860 workType "article" @default.